Orion Corporation’s partner Bayer submits sNDA to US FDA for oral androgen receptor inhibitor darolutamide: Espoo, Finland Saturday, September 28, 2024, 15:00 Hrs [IST] Finnish ...
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...
The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.